| 000 | 01506 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515105558.0 | ||
| 264 | 0 | _c20080807 | |
| 008 | 200808s 0 0 fre d | ||
| 022 | _a0003-4266 | ||
| 024 | 7 |
_a10.1016/j.ando.2007.10.024 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSlama, G | |
| 245 | 0 | 0 |
_a[One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study]. _h[electronic resource] |
| 260 |
_bAnnales d'endocrinologie _cFeb 2008 |
||
| 300 |
_a36-46 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Angiopathies _xepidemiology |
| 650 | 0 | 4 |
_aDiabetic Nephropathies _xepidemiology |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyocardial Infarction _xepidemiology |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRosiglitazone |
| 650 | 0 | 4 |
_aThiazolidinediones _xtherapeutic use |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aEschwège, E | |
| 700 | 1 | _aBernard, M-H | |
| 700 | 1 | _aGrimaldi, A | |
| 700 | 1 | _aOppert, J-M | |
| 700 | 1 | _aPouchain, D | |
| 700 | 1 | _aBégaud, B | |
| 773 | 0 |
_tAnnales d'endocrinologie _gvol. 69 _gno. 1 _gp. 36-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ando.2007.10.024 _zAvailable from publisher's website |
| 999 |
_c17749327 _d17749327 |
||